Abstract |
PNU-159548 (4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin) is the lead compound of a novel class of cytotoxic agents (alkycyclines) with a unique mechanism of action combining DNA intercalation with alkylation of guanines in the DNA major groove. The objectives of two phase I studies were to assess the dose-limiting toxicities (DLTs), to determine the maximum tolerated dose (MTD) and to study the pharmacokinetics (PKs) of PNU-159548 and its active metabolite PNU-169884 when administered intravenously (i.v.) over 10 or 60 min to patients with advanced solid tumours. Patients were treated with escalating doses of PNU-159548, courses repeated every 21 days at doses ranging from 1.0 to 16 mg/m(2). For pharmacokinetic analysis, plasma sampling was performed during the first course and assayed using a validated high-performance liquid chromatographic assay with mass spectrometric detection. 69 patients received a total of 161 courses. The MTD was reached at 14 and 16 mg/m(2) in heavily (HP) and minimally pretreated/non-pretreated (MP) patients, respectively, with thrombocytopenia as the DLT. A hypersensitivity reaction was observed in 8 patients across all dose levels, characterised by fever with chills, erythema, facial oedema and dyspnoea. The PKs of PNU-159548 and PNU-169884 were linear over the dose range studied. A significant correlation was observed between the percentage decrease in platelet count and the AUC of PNU-159548. In these studies, the DLT of PNU-159548 was thrombocytopenia. The recommended dose for phase II studies of PNU-159548 is 12 and 14 mg/m(2) administered i.v. over 10 min, once every 21 days, in HP and MP patients, respectively.
|
Authors | M J A de Jonge, J Verweij, A van der Gaast, O Valota, O Mora, A S Th Planting, M A Mantel, S Van Den Bosch, M J Lechuga, F Fiorentini, D Hess, C Sessa |
Journal | European journal of cancer (Oxford, England : 1990)
(Eur J Cancer)
Vol. 38
Issue 18
Pg. 2407-15
(Dec 2002)
ISSN: 0959-8049 [Print] England |
PMID | 12460785
(Publication Type: Clinical Trial, Clinical Trial, Phase I, Journal Article)
|
Chemical References |
- 4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulfonyldaunorubicin
- Antibiotics, Antineoplastic
- Daunorubicin
|
Topics |
- Adult
- Aged
- Antibiotics, Antineoplastic
(adverse effects, pharmacokinetics, therapeutic use)
- Carcinoma, Non-Small-Cell Lung
(drug therapy, metabolism)
- Colorectal Neoplasms
(drug therapy, metabolism)
- Daunorubicin
(adverse effects, analogs & derivatives, pharmacokinetics, therapeutic use)
- Dose-Response Relationship, Drug
- Drug Hypersensitivity
(etiology)
- Female
- Hematologic Diseases
(chemically induced)
- Humans
- Lung Neoplasms
(drug therapy, metabolism)
- Male
- Middle Aged
- Nausea
(chemically induced)
- Neoplasms
(drug therapy, metabolism)
- Vomiting
(chemically induced)
|